` EX9 (Exelixis Inc) vs DAX Index Comparison - Alpha Spread

EX9
vs
DAX Index

Over the past 12 months, EX9 has underperformed DAX Index, delivering a return of 0% compared to the DAX Index's 21% growth.

Stocks Performance
EX9 vs DAX Index

Loading
EX9
DAX Index
Add Stock

Performance Gap
EX9 vs DAX Index

Loading
EX9
DAX Index
Difference

Performance By Year
EX9 vs DAX Index

Loading
EX9
DAX Index
Add Stock

Competitors Performance
Exelixis Inc vs Peers

DAX Index
EX9
ABBV
AMGN
GILD
VRTX
Add Stock

Exelixis Inc
Glance View

Economic Moat
Wide
Market Cap
6.8B EUR
Industry
Biotechnology

Exelixis Inc., founded in 1994, embarked on its journey in the biotech sector with a sharp focus on genomics and drug discovery. This San Francisco-based biopharmaceutical company has firmly imprinted its name within the oncology space, thanks to its innovative research and development endeavors. One of the company's flagship achievements is the development and commercialization of cabozantinib, a compound used to treat various types of cancer. Marketed under the brand names like Cabometyx and Cometriq, cabozantinib targets tumor growth and angiogenesis, the process through which tumors develop their own blood supply. By honing in on these therapeutic areas, Exelixis capitalizes on its robust pipeline and partnerships with other healthcare stakeholders, thus carving out a niche in precision medicine. The company's business model primarily revolves around the development, commercialization, and strategic licensing of its drug candidates. Through extensive research and collaborative efforts, Exelixis not only advances its own proprietary medications but also licenses out their discoveries to maximize outreach and revenue potential. Revenue streams are generated through product sales, developmental milestones, and royalties, with significant investments poured back into research to fuel future innovation. In the intricate dance of biotech, Exelixis thrives on balancing the risk of high research costs with the lucrative potential of breakthrough cancer treatments, demonstrating a conscious strategy of leveraging scientific expertise into a commercially viable portfolio.

EX9 Intrinsic Value
19.49 EUR
Overvaluation 8%
Intrinsic Value
Price
Back to Top